Skip Navigation


Human Molecular Genetics Advance Access originally published online on June 15, 2004
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
13/16/1677    most recent
ddh181v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (39)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Buchanan, G.
Right arrow Articles by Tilley, W. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Buchanan, G.
Right arrow Articles by Tilley, W. D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Molecular Genetics, 2004, Vol. 13, No. 16 1677-1692
DOI: 10.1093/hmg/ddh181
Human Molecular Genetics, Vol. 13, No. 16 © Oxford University Press 2004; all rights reserved

Structural and functional consequences of glutamine tract variation in the androgen receptor

Grant Buchanan1, Miao Yang1, Albert Cheong1, Jonathan M. Harris2, Ryan A. Irvine3, Paul F. Lambert1, Nicole L. Moore1,{dagger}, Michael Raynor1,{ddagger}, Petra J. Neufing1,§, Gerhard A. Coetzee3 and Wayne D. Tilley1,*

1Dame Roma Mitchell Cancer Research Laboratories, Adelaide University/Hanson Institute, Adelaide, SA, Australia, 2Centre for Molecular Biotechnology, School of Life Sciences, Queensland University of Technology, Brisbane, QLD, Australia and 3Departments of Molecular Microbiology and Immunology, Urology and Preventative Medicine, USC/Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA

Received February 6, 2004; Revised April 26, 2004; Accepted June 1, 2004

The androgen receptor (AR) gene contains a polymorphic trinucleotide repeat region, (CAG)n, in its N-terminal transactivation domain (NTD) that encodes a polyglutamine (polyQ) tract in the receptor protein. Whereas the length of the CAG repeat ranges from 6 to 39 in healthy individuals, the variations in repeat length both within and outside the normal range are associated with disease, including impaired spermatogenesis and Kennedy's disease, and with the risk of developing breast and prostate cancer. Whereas it has been proposed that the inverse relationship between polyQ tract length within the normal range and AR transactivation potential may be responsible for altered risk of disease, the molecular mechanisms underlying polyQ length modulation of AR function have not been elucidated. In this study, we provide detailed characterization of a somatic AR gene mutation detected in a human prostate tumor that results in interruption of the polyQ tract by two non-consecutive leucine residues (AR-polyQ2L). Compared with wtAR, AR-polyQ2L exhibits disrupted inter-domain communication (N/C interaction) and a lower protein level, but paradoxically has markedly increased transactivation activity. Molecular modeling and the response to cofactors indicate that the increased activity of AR-polyQ2L results from the presentation of a more stable platform for the recruitment of accessory proteins than wild-type AR. Analysis of the relationship between polyQ tract length and AR function revealed a critical size (Q16–Q29) for maintenance of N/C interaction. That between 91 and 99% of AR alleles in different racial-ethnic groups encode a polyQ tract in the range of Q16–Q29 suggests that N/C interaction has been preserved as an essential component of androgen-induced AR signaling.

* To whom correspondence should be addressed at: Dame Roma Mitchell Cancer Research Laboratories, Adelaide University/Hanson Institute, PO Box 14 Rundle Mall, Adelaide, SA 5000, Australia. Tel: +61 882223225; Fax: +61 882223217; Email: wayne.tilley{at}imvs.sa.gov.au


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 EndocrinologyHome page
V. T. Todorov, M. Desch, T. Schubert, and A. Kurtz
The Pal3 Promoter Sequence Is Critical for the Regulation of Human Renin Gene Transcription by Peroxisome Proliferator-Activated Receptor-{gamma}
Endocrinology, September 1, 2008; 149(9): 4647 - 4657.
[Abstract] [Full Text] [PDF]

Home page
 GeneticsHome page
H. Niculita-Hirzel, M. Stock, and N. Perrin
A Key Transcription Cofactor on the Nascent Sex Chromosomes of European Tree Frogs (Hyla arborea)
Genetics, July 1, 2008; 179(3): 1721 - 1723.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
M. A. Albertelli, O. A. O'Mahony, M. Brogley, J. Tosoian, M. Steinkamp, S. Daignault, K. Wojno, and D. M. Robins
Glutamine tract length of human androgen receptors affects hormone-dependent and -independent prostate cancer in mice
Hum. Mol. Genet., January 1, 2008; 17(1): 98 - 110.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. Buchanan, C. Ricciardelli, J. M. Harris, J. Prescott, Z. C.-L. Yu, L. Jia, L. M. Butler, V. R. Marshall, H. I. Scher, W. L. Gerald, et al.
Control of Androgen Receptor Signaling in Prostate Cancer by the Cochaperone Small Glutamine Rich Tetratricopeptide Repeat Containing Protein {alpha}
Cancer Res., October 15, 2007; 67(20): 10087 - 10096.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
P. Crabbe, V. Bogaert, D. De Bacquer, S. Goemaere, H. Zmierczak, and J. M. Kaufman
Part of the Interindividual Variation in Serum Testosterone Levels in Healthy Men Reflects Differences in Androgen Sensitivity and Feedback Set Point: Contribution of the Androgen Receptor Polyglutamine Tract Polymorphism
J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3604 - 3610.
[Abstract] [Full Text] [PDF]

Home page
 J Mol EndocrinolHome page
F. F Brockschmidt, M. M Nothen, and A. M Hillmer
The two most common alleles of the coding GGN repeat in the androgen receptor gene cause differences in protein function
J. Mol. Endocrinol., July 1, 2007; 39(1): 1 - 8.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
J. M. Schildkraut, S. K. Murphy, R. T. Palmieri, E. Iversen, P. G. Moorman, Z. Huang, S. Halabi, B. Calingaert, A. Gusberg, J. R. Marks, et al.
Trinucleotide Repeat Polymorphisms in the Androgen Receptor Gene and Risk of Ovarian Cancer
Cancer Epidemiol. Biomarkers Prev., March 1, 2007; 16(3): 473 - 480.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. Werner, P.-M. Holterhus, G. Binder, H.-P. Schwarz, M. Morlot, D. Struve, C. Marschke, and O. Hiort
The A645D Mutation in the Hinge Region of the Human Androgen Receptor (AR) Gene Modulates AR Activity, Depending on the Context of the Polymorphic Glutamine and Glycine Repeats
J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3515 - 3520.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
M. A. Albertelli, A. Scheller, M. Brogley, and D. M. Robins
Replacing the Mouse Androgen Receptor with Human Alleles Demonstrates Glutamine Tract Length-Dependent Effects on Physiology and Tumorigenesis in Mice
Mol. Endocrinol., June 1, 2006; 20(6): 1248 - 1260.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
L. M. Butler, M. M. Centenera, P. J. Neufing, G. Buchanan, C. S. Y. Choong, C. Ricciardelli, K. Saint, M. Lee, A. Ochnik, M. Yang, et al.
Suppression of Androgen Receptor Signaling in Prostate Cancer Cells by an Inhibitory Receptor Variant
Mol. Endocrinol., May 1, 2006; 20(5): 1009 - 1024.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
Y.-T. Sheu, J. M. Zmuda, J. A. Cauley, S. P. Moffett, C. J. Rosen, C. Ishwad, and R. E. Ferrell
Nuclear Receptor Coactivator-3 Alleles Are Associated with Serum Bioavailable Testosterone, Insulin-Like Growth Factor-1, and Vertebral Bone Mass in Men
J. Clin. Endocrinol. Metab., January 1, 2006; 91(1): 307 - 312.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. Buchanan, S. N. Birrell, A. A. Peters, T. Bianco-Miotto, K. Ramsay, E. J. Cops, M. Yang, J. M. Harris, H. A. Simila, N. L. Moore, et al.
Decreased Androgen Receptor Levels and Receptor Function in Breast Cancer Contribute to the Failure of Response to Medroxyprogesterone Acetate
Cancer Res., September 15, 2005; 65(18): 8487 - 8496.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Alvarado, L. K. Beitel, K. Sircar, A. Aprikian, M. Trifiro, and B. Gottlieb
Somatic Mosaicism and Cancer: A Micro-Genetic Examination into the Role of the Androgen Receptor Gene in Prostate Cancer
Cancer Res., September 15, 2005; 65(18): 8514 - 8518.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. L. Terry, I. De Vivo, L. Titus-Ernstoff, M.-C. Shih, and D. W. Cramer
Androgen Receptor Cytosine, Adenine, Guanine Repeats, and Haplotypes in Relation to Ovarian Cancer Risk
Cancer Res., July 1, 2005; 65(13): 5974 - 5981.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.